10x Genomics (NASDAQ:TXG) Given Average Recommendation of “Hold” by Brokerages

10x Genomics (NASDAQ:TXG) has been given a consensus recommendation of “Hold” by the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $13.6538.

A number of analysts recently weighed in on the company. Barclays restated an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a report on Monday, August 11th. Zacks Research downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Friday, September 5th. Bank of America increased their price objective on 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday, June 26th. Finally, Piper Sandler initiated coverage on 10x Genomics in a report on Thursday, September 11th. They issued a “neutral” rating and a $15.00 price objective for the company.

10x Genomics Price Performance

NASDAQ TXG opened at $12.39 on Thursday. The business has a fifty day moving average price of $13.23 and a two-hundred day moving average price of $10.97. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $21.47. The stock has a market capitalization of $1.54 billion, a PE ratio of -17.70 and a beta of 2.06.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.63. The business had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.10x Genomics’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, sell-side analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the sale, the chief financial officer owned 309,273 shares of the company’s stock, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the sale, the chief executive officer directly owned 945,892 shares in the company, valued at $13,043,850.68. This trade represents a 0.98% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,149 shares of company stock valued at $539,865. 9.39% of the stock is currently owned by insiders.

Institutional Trading of 10x Genomics

A number of institutional investors have recently bought and sold shares of TXG. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after acquiring an additional 4,987,195 shares during the last quarter. Millennium Management LLC boosted its position in shares of 10x Genomics by 434.5% during the 1st quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock worth $46,946,000 after purchasing an additional 4,371,327 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of 10x Genomics by 241.3% during the 2nd quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company’s stock worth $47,916,000 after purchasing an additional 2,925,372 shares in the last quarter. Quantinno Capital Management LP boosted its position in shares of 10x Genomics by 207.2% during the 2nd quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company’s stock worth $25,864,000 after purchasing an additional 1,506,530 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of 10x Genomics by 3,619.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company’s stock worth $10,185,000 after purchasing an additional 1,135,356 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.